Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NASIMMUNE: LAIV Immunogenicity and Microbiome in Gambian Children
NCT02972957Phase 4Completed
- Sponsor
- London School of Hygiene & Tropical Medicine
- Start
- Jan 2017
- Primary completion
- Dec 2018
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Ganwu in influenza (4 arms), sponsored by London School of Hygiene & Tropical Medicine. Primary endpoints: Nasal IgA response, Fold increase in oral fluid influenza-specific/total IgA ratio at Day 21 and 1 more. Started Jan 2017; status: completed.
02
Drugs
Ganwu
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02972957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02972957.